J. Joseph Kim, Ph.D.

President, Chief Executive Officer, Director

JOSEPH KIM was appointed President and CEO of Inovio Pharmaceuticals in June 2009. Dr. Kim co-founded VGX Pharmaceuticals, a synthetic vaccine company, in 2000 to develop intellectual property related to immunotherapeutics licensed from the University of Pennsylvania. He led that company for nine years and combined VGX with Inovio Biomedical in 2009 to form Inovio Pharmaceuticals. Previously, Dr. Kim was a senior vaccine developer at Merck & Co. where he successfully led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV/AIDS.

Dr. Kim earned a Bachelor of Science degree in Chemical Engineering and Economics from the Massachusetts Institute of Technology (MIT), where he was a U.S. Senate Honors Scholar. He holds a PhD in Biochemical Engineering from the University of Pennsylvania and a Master of Business Administration degree in Finance from the Wharton School. Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents and sits on several editorial boards and review panels.

Dr. Kim has been recognized with numerous honors in the past several years, including:

2002: MIT's Technology Review, one of the world's Top 100 Young Innovators
2002: Philadelphia Business Journal, one of "40 under 40" dynamic professionals
2003 & 2006: Details Magazine, selected as one of "50 Most Influential Men"
2004: World Economic Forum, selection of Dr. Kim and VGX Pharmaceuticals as one of 30 Technology Pioneers
2005: Newsweek International, profiled in annual "Who's Next" issue as one of 10 leaders, scientists, and executives at the forefront of change and impact in the world
2006: Forum of Young Global Leaders, an affiliate of the World Economic Forum, named a Young Global Leader among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries.
2012: Member, The Global Agenda Council of the World Economic Forum;
Life Sciences CEO of the Year 
2013: Board of Trustees, International Vaccine Institute;
Achievement in Drug Discovery and Development Award from the Korean American Society in Biotech and Pharmaceuticals  

Peter Kies

Chief Financial Officer

PETER KIES has been Chief Financial Officer of Inovio since 2002. During the prior 16 years, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from IPO to profitability. He was previously Chief Financial Officer at Newgen Results Corporation and held positions at Cytel Corporation and Ernst & Young, LLP. Mr. Kies holds a Bachelor of Science degree in Business Administration from United States International University in San Diego, California.

 

Niranjan Y. Sardesai, Ph.D.

Chief Operating Officer

NIRANJAN Y. SARDESAI was appointed Chief Operating Officer of Inovio in January 2012. He served as the Company’s Senior Vice President of Research and Development following the June 2009 merger with VGX Pharmaceuticals, at which company he held the same position. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw research and development and expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer.

Dr. Sardesai received a Doctor of Philosophy degree in Chemistry from the California Institute of Technology and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He completed fellowships at Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.

Mark L. Bagarazzi, M.D.

Chief Medical Officer

MARK L. BAGARAZZI joined Inovio in January 2010 from Merck & Co., where he was Director of Worldwide Regulatory Affairs, responsible for vaccines and biologics. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also successfully led the regulatory process culminating in FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi is a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania School of Medicine. Previously he was an assistant professor of pediatrics at Drexel College of Medicine and a guest lecturer at Johns Hopkins University.

Dr. Bagarazzi holds a Bachelor of Science degree in electrical engineering, magna cum laude, from the New Jersey Institute of Technology and received his MD degree with honors from the University of Medicine and Dentistry of New Jersey. He holds several patents and has co-authored dozens of scientific papers focused on the subject of DNA vaccines that have been published in peer-reviewed medical journals.

Thomas Kim, Esq.

General Counsel and Corporate Secretary

THOMAS KIM is an experienced corporate attorney and a registered patent attorney, and has served as the senior in-house counsel for Inovio, and its predecessor companies, since 2007.  He leads the legal department as General Counsel, and he also serves as the Corporate Secretary.  At Inovio, he has built an intellectual property department from the ground up, and has overseen the integration of portfolios from several M&A deals.  In addition, Mr. Kim works with senior management and the Board on a regular basis on various corporate matters, including mergers and acquisitions, agreements, corporate financing, employment, and compliance and risk management.

Mr. Kim has counseled pharmaceutical and biotechnology companies for over 14 years. He has practiced law at both large law firms and at Fortune 100 companies including Monsanto and DuPont.  Prior to Inovio, Mr. Kim served as Senior Counsel to the gene discovery group at DuPont Company, where he provided legal counsel on a variety of patent issues and drafted and prosecuted patent applications related to DNA molecules and transgenic organisms.

Mr. Kim received a J.D. from Washington University School of Law in St. Louis, a M.S. in Biochemistry from the University of Illinois, and a B.S. in Chemistry from the Georgia Institute of Technology. He is licensed to practice law in the Commonwealth of Pennsylvania, State of Illinois, and is registered to practice before the U.S. Patent and Trademark Office.

Stephen Kemmerrer

Vice President, Engineering Operations

STEPHEN KEMMERRER is responsible for engineering, manufacturing, materials, distribution and all quality and regulatory aspects of electroporation instruments used in the delivery of Inovio’s synthetic vaccines.  Prior to joining Inovio in 2007, he held senior engineering and management positions at K2 Engineering, CancerVax and BioSite.  In 2002, he co-founded Sorrento BioSurgical, a start-up based on human tissue mesh technology.  Previously, he was Director of Engineering at Advanced Tissue Sciences, Engineering Manager at Pacific Device and Project Engineer at Hughes Aircraft Space and Communications.  Mr. Kemmerrer holds a BS in Mechanical Engineering from UC Berkeley and an MBA from San Diego State University.

 

EJ Brandreth, MBA

Vice President, Quality Assurance

E.J. BRANDRETH has over 30 years in life sciences including small molecules, devices and a wide variety of pivotal biotechnology products. He was previously Sr. Vice President of Quality and Regulatory Affairs at Ajinomoto Althea Technologies, specializing in CMO biotech processing and aseptic filling. He was the Sr. Director of Quality for BioMarin where he helped build the commercial orphan drug facility and launched Aldurazyme® and Naglazyme®. During the start of IDEC Pharmaceuticals he held various management positions in QA, Validation and Regulatory Affairs, and was a core team member for the development and launch of Rituxan® and Zevalin®. He is the past Chairman of the PDA Biotech Advisory Board, and is the past President of ISPE, San Diego. He holds an MBA from UOP and a BA in Biology from UCSD.

 

Laurent Humeau, Ph.D.

Vice President, Research & Development

LAURENT HUMEAU is the Vice President of Research & Development, based at the Inovio San Diego Research Center. Laurent provides the technical and strategic leadership for the R&D group including: preclinical development of immunotherapy and vaccine candidates, immunology and immune monitoring approaches, method development, product characterization, and analytical development. Prior to Inovio, Laurent was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Laurent holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 university and a MS degree from Pierre & Marie Curie/Paris 6 university, Paris, France.